Dr. Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India
April 13 2021 - 2:03AM
Business Wire
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, NSEIFSC: DRREDDY) today announced that it has received the
permission from the Drug Controller General of India (DCGI) to
import the Sputnik vaccine into India for restricted use in
emergency situations as per the provisions of the New Drug and
Clinical Trials rules, 2019 under the Drugs and Cosmetics Act.
In September 2020, Dr. Reddy’s had partnered with the Russian
Direct Investment Fund (RDIF) to conduct the clinical trials of
Sputnik V and distribute the vaccine in India. In addition to the
trials conducted in Russia by RDIF. Phase II / III clinical trials
of the vaccine were carried out by Dr. Reddy’s in India.
Dr Reddy’s Laboratories co-chairman and managing director GV
Prasad said, “We are very pleased to obtain the emergency use
authorisation for Sputnik V in India. With the rising cases in
India, vaccination is the most effective tool in our battle against
COVID-19. This will enable us to contribute to our nation’s effort
of vaccinating a significant proportion of our population.”
Sputnik V is now approved for use in 60 countries around the
world. It ranks second among coronavirus vaccines globally in terms
of the number of approvals issued by government regulators. Sputnik
V uses two different vectors for the two shots in a course of
vaccination. The efficacy of Sputnik V was determined to be 91.6%
as per a published article in the Lancet, one of the world's oldest
and most respected medical journals.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated
pharmaceutical company, committed to providing affordable and
innovative medicines for healthier lives. Through its three
businesses - Pharmaceutical Services & Active Ingredients,
Global Generics and Proprietary Products – Dr. Reddy’s offers a
portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars and differentiated
formulations. Our major therapeutic areas of focus are
gastrointestinal, cardiovascular, diabetology, oncology, pain
management and dermatology. Dr. Reddy’s operates in markets across
the globe. Our major markets include – USA, India, Russia & CIS
countries, and Europe. For more information, log on to:
www.drreddys.com.
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on
the management’s current views and assumptions and involve known or
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. In addition to statements which are
forward-looking by reason of context, the words "may", "will",
"should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar
expressions identify forward-looking statements. Actual results,
performance or events may differ materially from those in such
statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates, interest rates, persistency
levels and frequency / severity of insured loss events, (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues, and (vi) the
susceptibility of our industry and the markets addressed by our,
and our customers’, products and services to economic downturns as
a result of natural disasters, epidemics, pandemics or other
widespread illness, including coronavirus (or COVID-19), and (vii)
other risks and uncertainties identified in our public filings with
the Securities and Exchange Commission, including those listed
under the "Risk Factors" and "Forward-Looking Statements" sections
of our Annual Report on Form 20-F for the year ended March 31,
2020. The company assumes no obligation to update any information
contained herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210412006057/en/
INVESTOR RELATIONS AMIT AGARWAL amita@drreddys.com (Ph:
+91-40-49002135)
MEDIA RELATIONS PRANAV PRIMLANI
pranav.primlani@drreddys.com (PH: +91- 9381905796)
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024